hw8

hw8

by Mitzi Hawkins -
Number of replies: 1

1. What are 3 different ways to account for SES in a analytic models when investigating racial/ethnic health disparities? Briefly discuss the interpretations/implications of each approach as it relates to understanding health disparities by race/ethnicity.

 

Effect modifier: as SES changes, this changes the magnitude of association of the outcome. Helpful to determine how differing SES may impact outcomes among different race/ethnicity groups.

 

Effect mediator: if we consider SES an effect mediator we can include it in a model to attempt to understand the disparity attributable directly to race/ethnicity (or other uncontrolled for mediators) when known common causes are controlled for. Helpful to attempt to describe disparity directly associated with race/ethnicity

 

Contextual effect: group (eg neighborhood) SES may impact individual association between race/ethnicity and health outcome/disparity. May be helpful to understand how community or surrounding environs impact health outcomes.

 

2. Describe a potential effect modifier, mediator, or contextual variable (for definition of contextual variable, see Diez-Roux reading) for an association of interest to you and relevant to health disparities. For example, for investigating the association between education and hypertension, I might be interested in evaluating whether the association between years of education and hypertension is different for Black men than for White men. Describe how you would study whether this relationship exists.

 

I'm interested in the effect of testosterone on the development of endometrial neoplasia (cancer and precursor lesions). There is a known health disparity among Black women and white women in endometrial cancer diagnosis and survival. For me, it will be important to include race/ethnicity in my analysis to see if this disparity is replicated among trans people using testosterone therapy. I would include race/ethnicity as an effect modifier.


In reply to Mitzi Hawkins

Re: hw8 Q 3

by Curt Johanson -

HW8 Q3.


HI Mitzi,

I help with administration and data collection on a couple clinical trials on uterine fibroid treatments and I am intrigued by your question and wonder about differences in fibroids between women and men on various hormone therapy and uterine transplant (See attached Lancet Article on Uterine Transplant success from live and post mortem organ donors).  I had only heard of uterine fibroids before as a uncommon condition until working on studies here and have seen in the literature and in our studies higher prevalence rates, size and severity in Latin and African American patients. The fibroids can potentially lead to uterine cancers and they are extremely symptomatic and painful. For your study since cancer might be very difficult to have as an observational endpoint you could perhaps look at Fibroids as they develop very quick! I'm not an MD, but I seem to remember that estrogen seems to increase their growth and transxamic acid in some cases. Maybe a multi level analysis on trends across men and women with estrogen vs. t therapy ?